If you have read anything about epithalon in the past year, you have probably seen the same sentence recycled: an independent university study finally showed epitalon lengthens telomeres in human cells. That is true, and it matters. It is also only half of what the study reported.

The paper — Al-dulaimi and colleagues at Brunel University London, published in Biogerontology in September 2025 — ran two experiments, not one. The first used normal human cells. The second used breast cancer cell lines. Telomeres got longer in both, but by different mechanisms, and it is the second result that almost never makes it into the summaries. This post walks through what each arm actually tested, why the cancer-cell finding is an open question rather than a scare story, and where epithalon sits in Australia. For the compound background, see our epithalon profile.

What is epithalon, briefly

Epithalon (also written epitalon, or AEDG) is a synthetic tetrapeptide — alanine-glutamate-aspartate-glycine — derived from work on a bovine pineal extract called Epithalamin. The two are not the same thing and should not be used interchangeably: one is a defined four-amino-acid sequence, the other a crude tissue extract. Almost the entire published evidence base traces back to a single research lineage, Vladimir Khavinson's group in St Petersburg, which is precisely why an independent replication attracted attention.

Epithalon is not approved as a medicine anywhere in the world. There is no regulator — TGA, FDA or EMA — that has assessed it for safety, quality or efficacy in humans.

What the 2025 Brunel study actually did

The two arms of the study were not built the same way, and that is worth understanding before comparing their results.

Arm one: normal human cells

Normal human mammary epithelial cells (HMEC) and IBR.3 fibroblasts were exposed to epitalon at 1 µg/mL for three weeks. Using qPCR and immunofluorescence, the authors reported dose-dependent telomere lengthening, accompanied by upregulation of hTERT — the catalytic subunit of telomerase — and of telomerase activity itself.

This is the headline finding, and it is a genuine first: an independent Western laboratory, with no connection to the originating Russian group, observing the effect the original literature claimed.

Arm two: breast cancer cell lines

The second arm used two telomerase-positive breast cancer lines, 21NT and BT474, at 0.1–1 µg/mL for four days — not three weeks. Telomeres lengthened here too, but the authors attributed it to ALT, or alternative lengthening of telomeres, rather than to classical telomerase upregulation. ALT activation was reported as specific to the cancer lines; only a minor increase was seen in the normal cells.

Note the design asymmetry. Three weeks versus four days is not a like-for-like comparison, so "epitalon does X in normal cells and Y in cancer cells" is a cleaner story than the experiment supports. What you can say is that both cell types showed lengthening, and the proposed mechanisms differed.

Why the ALT result is an open question, not a verdict

ALT is a recombination-based route for maintaining telomeres that some tumours use instead of telomerase. A compound that appears to switch it on in cancer lines in a dish is a reason to ask more questions, not a reason to conclude anything about people.

Three honest qualifications:

  • This is cell culture. Immortalised cancer lines in a flask behave nothing like a tumour in a body with an immune system, vasculature and drug clearance. No in-vivo work has followed up this specific observation.
  • Effect sizes are not in the abstract. The abstract reports direction and mechanism, not quantified magnitude or p-values — so "how much" remains a question for the full text and for replication.
  • The originating literature points the other way. The Khavinson group's rodent work has long reported lower spontaneous tumour rates with epithalon and Epithalamin. That work has not been independently replicated either. Two unreplicated signals pointing in opposite directions is exactly the state of evidence that should make anyone cautious about confident claims in either direction.

There is also a correction on the record: in November 2025 the journal published a correction stating that incorrect versions of Figures 1, 2 and 3 had appeared in the original article, with the correct figures supplied by the authors. It is a figure-handling correction, not a retraction of the conclusions — but if a paper is going to be cited as the turning point in epithalon research, the corrected version is the one to read.

Is epithalon legal in Australia? The regulatory reality

Epithalon has never been entered on the Australian Register of Therapeutic Goods. That makes any epithalon product presented for human therapeutic use an unapproved therapeutic good, regardless of how a website labels it.

The TGA has been unusually direct on this category. It has issued a consumer safety alert on the risks of importing unapproved peptide products, warning that such products have not been assessed for safety, quality or effectiveness and that buyers often cannot know what is actually in the vial. It has separately put promoters and suppliers on notice, flagging warning letters, infringement notices, seizures, civil penalties and in serious cases criminal prosecution. Australian Border Force interception of peptide shipments is routine.

The practical Australian takeaway: the 2025 study changes what we know about epithalon in a dish. It changes nothing about its regulatory status here, and nothing about product quality in an unregulated supply chain. We cover the wider category in our peptides section.

What would actually settle this

For the normal-cell finding: independent replication in a second laboratory, then in-vivo work showing the same telomerase response in living tissue — and eventually a controlled human study measuring telomere length before and after, which has never been done to a modern standard.

For the cancer-cell finding: a straightforward xenograft or rodent tumour study asking whether ALT activation happens outside a flask, and whether it has any consequence. Until someone runs it, the question stays open, and anyone telling you it is settled — in either direction — is ahead of the data.

Want these breakdowns as they publish? Join the free updates list.

FAQ

What is epithalon and what does it do?

Epithalon (epitalon, AEDG) is a synthetic tetrapeptide developed from pineal gland research, studied mainly for telomerase activation and circadian effects. Nearly all of its evidence is preclinical or comes from a single Russian research group, and it is not approved as a medicine anywhere.

Does epithalon lengthen telomeres in humans?

A 2025 Brunel University London study reported telomere lengthening in normal human cells in culture — the first independent replication of that claim. No controlled human trial has measured telomere length before and after epithalon use, so the effect in living people is unestablished.

Is epithalon linked to cancer?

The same 2025 study reported telomere lengthening in two breast cancer cell lines via ALT activation, which was largely specific to those lines. That is an in-vitro observation with no animal or human follow-up — it is an unanswered question, not evidence of harm in people.

Is epithalon legal in Australia?

Epithalon is not on the ARTG and is not approved for human therapeutic use in Australia. The TGA has issued safety alerts about unapproved peptide products and warned importers, suppliers and promoters that it is actively enforcing in this area.

Sources

This article is information only, not medical advice. Epithalon is an investigational compound not approved as a medicine in Australia or anywhere else. retatrutide.net.au is independent and does not sell or source peptides.